David Molkentine - Concepedia

Concepedia

Author

David Molkentine

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

D P Molkentine, D. Molkentine, D.P. Molkentine, David Molkentine, David P Molkentine, David P. Molkentine, Molkentine, D P

161

Publications

1.3K

Citations

20

H-Index

29

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Southwestern Medical Center Stanford University UPMC Hillman Cancer Center Baylor College of Medicine

DM

About

David Molkentine is an author at The University of Texas MD Anderson Cancer Center specializing in cancer research, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	479
2	Cell Biology	5	5	357
3	Health Sciences	2	2	85
4	Immunology	2	2	190
5	Pathology	2	2	85

David Molkentine

×

24

Publications

1.3K

Citations

20

H-Index

	Year	Citations
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma Yu Qian, Ana Galan Cobo, Irene Guijarro, Cancer Cell MedicineImmunologyTumor ImmunityTumor SuppressorMct4-dependent Lactate Secretion	2023	153
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Nature	2024	117
Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer Heath D. Skinner, Uma Giri, Liang Yang, Clinical Cancer Research	2017	115
DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy Benjamin J. Moeller, John S. Yordy, Michelle D. Williams, Clinical Cancer Research	2011	92
Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <i>In Vivo</i> and <i>In Vitro</i> Daisuke Sano, Fumihiko Matsumoto, David R. Valdecanas, Clinical Cancer Research	2011	75
Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer Heath D. Skinner, Uma Giri, Liang Yang, Clinical Cancer Research	2016	75
C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression Vikas Bhardwaj, Yanai Zhan, María Angélica Cortez, Journal of Thoracic Oncology Tumor BiologyRadiation MedicineRadiation TherapyMedicinePharmacology	2012	72
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways Uma Raju, Oliver Riesterer, Zhiqiang Wang, Radiotherapy and Oncology ChromatinRadiation OncologyRadiation TherapyMulti-kinase InhibitorDna Repair Pathways	2012	55
TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects L. Wang, Peijing Zhang, David Molkentine, Oncogene Radiation MedicineCancer-associated VirusRadiation TherapyHuman Papillomavirus VaccinesMedicine	2016	54
A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe Oliver Riesterer, Fumihiko Matsumoto, Li Wang, Investigational New Drugs Cancer ResearchOncologyNovel Chk InhibitorMedicineReceptor Tyrosine Kinase	2009	50

Page 1